Roche’s Giredestrant Advances Oral SERD Debate at ESMO 2025
Giredestrant, an oral SERD from Roche, showed promising results in extending progression-free survival (PFS) for patients with ER-positive, HER2-negative advanced breast cancer when combined with everolimus.
The Evera trial's data indicated better performance compared to other oral SERDs in the ESR1 wild-type population.
Giredestrant's success raises questions about its potential label and approval by regulators.